New hope for head and neck cancer patients who failed chemo?

This study tests whether adding an experimental drug (ficerafusp alfa) to a standard immunotherapy (nivolumab) can shrink tumors better than nivolumab alone in people with advanced head and neck cancer that stopped responding to platinum chemotherapy. About 131 adults whose cancer worsened within 6 months of prior treatment will participate. The goal is to see if the combination improves the number of patients whose tumors shrink significantly.